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Cellular/Molecular

A Portable Site: A Binding Element for 17␤-Estradiol Can Be
Placed on Any Subunit of a Nicotinic ␣4␤2 Receptor
Xiaochun Jin and Joe Henry Steinbach
Department of Anesthesiology, Washington University School of Medicine, Saint Louis, Missouri 63110

Endogenous steroids can modulate the activity of transmitter-gated channels by directly interacting with the receptor. 17␤-Estradiol
potentiates activation of neuronal nicotinic ␣4␤2 receptors by interacting with a 4 aa sequence at the extreme C terminus of the ␣4
subunit, but it is not known whether potentiation requires that the sequence be placed on a specific subunit (e.g., an ␣4 subunit that is
involved in forming an acetylcholine-binding site). By using concatemers of subunits and chimeric subunits, we have found that the
C-terminal domain can be moved from the ␣4 to the ␤2 subunit and still result in potentiation. In addition, the sequence can be placed on
a subunit that contributes to an acetylcholine-binding site or on the structural subunit. The data indicate that this estradiol-binding
element is a discrete sequence and suggest that the effect of 17␤-estradiol is mediated by actions on single subunits and that the overall
consequences for gating occur because of the summation of independent energetic contributions to overall gating of this receptor.

Introduction
Steroids are endogenous modulators of membrane channel function. Although many actions of steroids are mediated by alterations
in gene expression initiated by binding to nuclear receptors, steroids
can have rapid and reversible actions on both transmitter-gated and
voltage-gated ion channels (Belelli and Lambert, 2005; Schlichter et
al., 2006). A particularly well studied example is the GABA type A
(GABAA) receptor, for which neurosteroids are among the most
potent and efficacious potentiators (Belelli and Lambert, 2005; Akk
et al., 2007). The fact that steroids can modulate the function of
synaptic receptors provides a rapid link between endocrine and nervous system functions.
The ligand-gated ion channel gene family includes the subunits for the vertebrate nicotinic, GABAA, serotonin type 3, and
glycine receptors, and a number of related proteins in invertebrates (Brejc et al., 2001; Akabas, 2004; Sine and Engel, 2006).
These receptors form as pentamers of homologous subunits (see
Fig. 1), arranged in a rosette around a central ion channel formed
from membrane-spanning ␣-helical regions contributed from all
subunits. We are studying the neuronal nicotinic receptor containing ␣4 and ␤2 subunits, to define the sites and mechanisms by
which potentiating agents act on the receptor. The ␣4 subunit is
expressed in many brain regions, and the ␣4␤2* receptor is one of
the most common receptor subtypes (Gotti et al., 2007). The
major physiological role of these receptors is to modulate the
release of other neurotransmitters (Dani and Bertrand, 2007).
The endogenous steroid 17␤-estradiol potentiates the response

of the ␣4␤2 nicotinic receptor and requires a specific amino
acid sequence at the extreme C terminus of the ␣4 subunit
(Paradiso et al., 2001; Curtis et al., 2002). We sought to better
define the structural requirements for estradiol potentiation
of this receptor.
The sites at which potentiators interact with receptors in the
ligand-gated ion channel family have been defined for some
drugs. In several cases, the recognition region for the drug is
formed by residues from two subunits at an interface between
subunits (Hsiao et al., 2006; Moroni et al., 2008; Seo et al., 2009).
In others, binding occurs between residues in a single subunit
(Jenkins et al., 2001; Hosie et al., 2006; Li et al., 2006). By using
concatemeric constructs of subunits and mutated subunits, we
examined the effects of placing the ␣4 C-terminal sequence on
either the ␣4 or ␤2 subunit, or on subunits that contribute an
interface to an ACh-binding site or that serve as the structural
subunit (see Fig. 1). Our results show that the C-terminal sequence may be placed on either subunit and the subunit may be
in either position in the assembled receptor. These observations
indicate that the C-terminal domain is a discrete and transferable
element underlying 17␤-estradiol potentiation. Potentiation increases geometrically with the number of C-terminal domains in
the receptor, which suggests that binding of 17␤-estradiol has an
independent effect on an individual subunit, which adds a constant amount of energy to stabilize the open-channel form of the
receptor.
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cDNAs and molecular biology. cDNA constructs for human nicotinic receptor ␣4 and ␤2 subunits were kindly provided by J. Lindstrom (University of Pennsylvania, Philadelphia, PA) (␣4, accession number
NM_000744; ␤2, accession number NM_000748). The constructs were
transferred to pcDNA3 (Invitrogen).
Two concatemers were constructed, which linked two subunits, as
previously described (Zhou et al., 2003). From the N to C termini, they
are ␤2-EF(AGS)6-␣4 (abbreviated ␤/␣) and ␣4-EF(AGS)8-␤2 (␣/␤).

5046 • J. Neurosci., March 30, 2011 • 31(13):5045–5054

Jin and Steinbach • A Discrete Estradiol-Binding Site

The signal sequence of the second subunit was
deleted. The ␤/␣ concatemer is very similar to
that described previously (Zhou et al., 2003)
[EG(AGS)6], whereas the ␣/␤ concatemer
has a linker two residues longer than the ␣4(AGS)6-␤2 concatemer described previously
[QEGT(AGS)6TG]. Chimeric subunits were
constructed by overlap extension and smaller
mutations were constructed using QuikChange
(Stratagene). The locations of chimera joining
points are shown in Figure 1.
All constructs were sequenced through the
entire coding region.
Receptor expression and oocyte voltage clamp.
cRNA was synthesized using the mMessage
mMachine T7 kit (Ambion). The concentration of mRNA was estimated from the OD260
value. When combinations of free subunits
were injected, the ratio of construct with an ␣4
N terminus to that with a ␤2 N terminus was
8:1 (mass ratio), unless otherwise specified.
When concatemers were injected with free
subunits, the ratio was 2:1.
Xenopus oocytes were prepared in the laboratory of Dr. C. Zorumski (Washington University, St. Louis, MO) using an approved
Figure 1. Schematic views of the receptor and subunits. The top panel shows the overall arrangements in pentamers containing
protocol. Oocytes were injected with 12–15 ng
concatemers. Subunits are arranged around the ion channel (dotted circle). ACh-binding sites are indicated by the diamonds
of cRNA in a volume of 18 –23 nl. Oocytes were
between an ␣4 subunit (contributing the positive or ⫹ side of the interface) and a ␤2 subunit. Four subunits contribute to the
maintained at 18°C for 2–7 d before physiologagonist-binding sites, whereas the fifth occupies a “structural” position. The concatemers are indicated with linkers connecting the
ical study.
C terminus (denoted by a circle with C) to the N terminus, as shown by the arrowheads. The fainter diamonds on the free subunit
Standard methods were used for twoassembled with the ␣/␤ concatemer indicate that the site is located on opposite sides, depending on the nature of the N-terminal
electrode voltage clamp of Xenopus oocytes
sequence of the free subunit (note that the structural subunit in this combination is contributed from one of the concatemers). The
(Steinbach et al., 2000; Paradiso et al., 2001; Jin
bottom panel shows the constructs used. The top pair shows sequence for the chimeras ␣-M3-␤ and ␤-M3-␣. The line above the
et al., 2009), using an OC-725C voltage clamp
sequences shows the position of the C-terminal end of the M3 region. The joining point is indicated by the arrow; the sequences
(Warner Instruments). Currents were filtered
were swapped for all positions including and following the indicated residue. The bottom pair shows the ␤M43 C and ␤WLAGMI
at 20 Hz, and then digitized at 50 Hz (Digidata
constructs. The line shows the position of the predicted M4 region. The bold letters indicate amino acid residues in the predicted M4
1200 interface; Molecular Devices) and stored
region that differ between ␣4 and ␤2.
using pClamp 8.0 (Molecular Devices). Transients were analyzed with Clampfit (Molecular
lowed by repeat of the control low concentration. The relative response
Devices). Oocyte recordings were performed in a small chamber that was
in the presence of 17␤-estradiol was then calculated. 17␤-Estradiol was
continuously perfused with saline. Drug applications were made using a
not preapplied, as the onset and offset of potentiation are rapid (Paradiso
manually controlled perfusion system. The system was made with glass,
et al., 2001). ACh or ACh plus 17␤-estradiol were applied for 10 –20 s,
stainless-steel, or Teflon components, to reduce steroid adsorption. The
and
applications were separated by 3– 4 min, to allow full washout.
applications were relatively slow, with bath exchange times of ⬃1 s. The
The amplitudes of currents expressed by some combinations of conexternal solution contained the following (in mM): 96 NaCl, 2 KCl, 1.8
structs were much larger than for others (supplemental Table 1, available
BaCl2, 1 MgCl2, and 10 HEPES, pH 7.3. External Ca 2⫹ was replaced with
at www.jneurosci.org as supplemental material). We are exploring posBa 2⫹, to avoid activation of Ca 2⫹ activated channels. We did not use
sible reasons for this, but do not have an explanation at present. Experiatropine to block muscarinic receptors, as it potentiates ␣4␤2 receptors
mentally, to accept a value for potentiation by 17␤-estradiol, the control
(Zwart and Vijverberg, 1997). Occasional oocytes showed delayed reresponse had to be at least 5 nA. For analysis of agonist concentration–
sponses to ACh; these oocytes were discarded.
response relationships, the maximal response had to be at least 50 nA. To
The concentration–response relationship for activation by ACh was
avoid problems of clamp control, the maximal response also had to be
characterized by fitting the Hill equation, Y([ACh]) ⫽ Ymax(1/(1 ⫹
⬍30 A. For some constructs, the low response amplitude required us to
(EC50/[ACh]) ^nHill)), where Y is the response to a concentration of ACh,
use a higher than usual concentration of ACh, which might have reduced
Ymax is the maximal response, EC50 is the concentration producing halfthe estimated potentiation (supplemental Table 2, available at www.
maximal activation, and nHill is the Hill coefficient. Concentration–rejneurosci.org as supplemental material).
sponse data were collected for an individual cell, and data were
Values are presented as arithmetic mean ⫾ SE (number of observanormalized to the response to 1 mM ACh. The fit was rejected if the
tions). Statistical tests were made using Excel (Microsoft) or Systat (Sysestimated error in any fit parameter was ⬎60% of the fit value, and all
tat Software). Unless otherwise indicated, statistical tests were two-tailed
parameter estimates for that fit were discarded. The relationship was
t tests with unequal variance.
analyzed for each cell, and then overall mean values were calculated for
Receptor extraction and Western blots. Groups of 40 –50 oocytes were
oocytes injected with that set of constructs.
injected with mRNA, as described previously. Membrane proteins were
Potentiation by 17␤-estradiol is strongest for low concentrations of
extracted basically as described previously (Carbone et al., 2009). In brief,
ACh (Paradiso et al., 2001; Curtis et al., 2002). Since the EC50 for activaoocytes were suspended in an ice-cold homogenization buffer containing
tion by ACh depends on the subunit combinations expressed (see Rethe following (in mM): 150 NaCl, 2 CaCl2, 2% Triton X-100, 20 Tris-HCl,
sults), each oocyte was tested with 1 mM ACh, to estimate the maximal
pH 7.4, supplemented with protease inhibitor mixture (Sigma-Aldrich;
response. A low concentration of ACh, chosen to be able to evoke ⬍20%
P8465), at a ratio of 5 l of buffer per oocyte. Oocytes were homogenized
of the maximal current, was then applied. After the response to ACh had
by passing through a 20 gauge needle seven times and a 27 gauge needle
reached a stable level, the application was switched to ACh plus 10 M
17␤-estradiol. The application was switched to bathing solution, folthree times, and then extracted for 30 min on ice. Homogenates were
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Table 1. Basic characterization of receptors containing concatemers
ACh EC50 (M)
5I A85380 response

10 M 17␤-Estradiol

Combination

Mean

SE

N

Mean

SE

N

Mean

SE

N

p

␣4&␤2 1:8
␣4&␤2 8:1
␣/␤
␤/␣
␣/␤&␣4
␤/␣&␣4
␣/␤&␤2
␤/␣&␤2

6.6
131
105
121
87
140
2.9
4.4

1.4
11
23
16
8
14
0.6
0.8

14
25
18
48
33
43
12
29

1.44
0.19
0.16
0.44
0.14
0.17
1.84
1.59

0.06
0.03
0.01
0.04
0.01
0.01
0.07
0.07

11
9
16
62
29
46
16
34

2.56
2.96
0.85
3.17
1.47
3.77
1.04
3.73

0.12
0.30
0.06
0.25
0.07
0.20
0.06
0.32

7
12
5
6
27
11
11
7

0.000
0.000
0.047
0.000
0.000
0.000
0.560
0.000

The first column names the constructs injected. The next three columns give data on activation by ACh in terms of the EC50 value provided by a fit of the Hill equation. The three columns headed ⬙5I A85380 response⬙ give data on the response
to 1 M 5I A85380 normalized to the response to 1 mM ACh, for that cell. The columns headed ⬙10 M 17␤-Estradiol⬙ give data for the potentiation by 10 M 17␤-estradiol of a response to a low concentration of ACh; the column headed
p gives the probability that the potentiation ratio differs significantly from 1 (no effect), by two-tailed t test.

centrifuged twice at 1000 ⫻ g for 5 min at 4°C to remove the yolk, and the
supernatants were then recentrifuged at 10,000 ⫻ g for 10 min at 4°C. The
cleared supernatants were collected and diluted 50:50 in 2⫻ Laemmli
sample buffer (Bio-Rad) supplemented to 100 mM DTT. Samples were
placed at room temperature for 30 min, and then aliquots were loaded on
precast 7.5% gels (Bio-Rad). After electrophoresis, proteins were transferred to PVDF (polyvinylidene difluoride) membranes (Millipore).
Membranes were blocked for 1 h at room temperature with 100% Odyssey block solution (LI-COR Biosciences), followed by overnight incubation at 4°C in a solution of 50% Odyssey block solution/50% PBS (137
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3)
containing 0.4% Tween 20 (Sigma-Aldrich) with primary antibody.
Polyclonal rabbit antibody to ␣4 subunit (sc5591; Santa Cruz Biotechnology) and goat antibody to ␤2 (sc1449; Santa Cruz Biotechnology)
were used at 1:300. Membranes were washed four times with PBS containing 0.2% Tween 20, and then incubated with secondary antibody in
the dark for 45 min at room temperature. Goat anti-rabbit and donkey
anti-goat labeled with IR dye 680 (LI-COR Biosciences) were used at
dilutions between 1:5000 and 1:20,000. Membranes were washed five
times with PBS plus 0.2% Tween 20 and scanned on an Odyssey Infrared
Imaging System (LI-COR Biosciences).
Drugs. 17␤-Estradiol (CAS 50-28-2), acetylcholine chloride (ACh) (CAS
60-31-1), and 19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17␣)-(9CI)
(17␣-vinylestradiol) (CAS 57-63-6) were purchased from Sigma-Aldrich.
5-Iodo-3-(2( S)-azetidinylmethoxy)pyridine (5I A85380) (CAS 21376492-2) was purchased from Tocris. Steroids were prepared as a 20 mM stock
solution in DMSO and diluted into external solution on the day of an experiment. ACh was prepared as a 1 M stock solution in bath solution and stored
frozen at ⫺20°C. 5I A85380 was prepared as a 50 M stock solution in bath
solution and stored frozen at ⫺20°C. Working solutions were prepared on
the day of experiments.
Characterization of receptors containing concatemers. We wanted to
control the subunit stoichiometry and subunit position in ␣4␤2 receptors. To accomplish this, we generated two concatemers, following the
approach described by Zhou et al. (2003), one with the ␤2 subunit at the
N terminus (abbreviated ␤/␣) and the other with ␣4 (␣/␤). We expressed
each concatemer in oocytes, both alone and with free ␣4 or ␤2 subunits
(Table 1). We confirmed that concatemers expressed alone produce
functional receptors. However, in the presence of a free subunit, the
resulting receptors appear to reflect the properties of receptors composed
of two concatemers plus a single free subunit (Zhou et al., 2003). Expression with a free ␤2 subunit results in a population of receptors with a
small EC50 for activation by ACh, whereas free ␣4 subunit results in
receptors with a large EC50 (Table 1). The values are similar to those for
free subunits expressed at a low ␣4:␤2 ratio or a high ␣4:␤2 ratio, respectively (Table 1) (Zwart and Vijverberg, 1998; Moroni et al., 2006). We
also examined gating by the subtype-selective agonist, 5I A85380. This
agonist has different EC50 values for activation of the two forms: ⬃10 nM
for (␣4)2(␤3)3 versus ⬃18,000 nM for (␣4)3(␤3)2 (Zwart et al., 2006). In
addition, the maximal response is actually greater than the maximal
response to ACh for the (␣4)2(␤3)3 receptor (Zwart et al., 2006). We
determined the response to 1 M 5I A85380 relative to the response to 1
mM ACh. 5I A85380 activates receptors incorporating free ␤2 (resulting

in receptors containing three copies of ␤2) much more strongly than
those with free ␣4, as expected from studies with free subunits (Table 1).
Overall, these results indicate that the concatemers assemble with free
subunits to generate pentameric receptors with properties appropriate
for the stoichiometry predicted for incorporation of the free subunit, as
reported previously (Zhou et al., 2003).
The fact that we produce surface receptors by combining subunit concatemers with mutated free subunits raises the possibility that some combinations assembled inappropriately (for example excluding the free
subunit). We cannot rule this out, but for most combinations we determined the EC50 for activation by ACh and the relative gating by 1 M 5I
A85380 compared with 1 mM ACh (supplemental Table 1, available at
www.jneurosci.org as supplemental material). As mentioned previously,
these values provide an indication of the numbers of ␣4 and ␤2 subunits
present in the functional receptors. Our unpublished data indicate that
the N-terminal extracellular domain is the primary determinant for both
of these parameters; that is, when three ␤2 extracellular domains are
present in the receptor, the EC50 will be small (10 M or less) and the
relative response to 5I A85380 will be large (1.0 or greater), in contrast to
the case when only two are present. Figure 2 shows a plot of relative
response against log(EC50) and shows that the data fall into two distinct
groups. The groups indicate that the functional receptors contain the
number of ␤2 extracellular domains expected if the free subunits incorporated into the pentameric receptor. As shown in Results, we also found
that a single free ␣4 subunit confers potentiation by 17␤-estradiol, indicating that it also incorporates into the assembled pentameric receptors.
Accordingly, the constructs we have used behave in the expected way,
and the majority of pentameric receptors include both concatemers and
free subunits. We cannot rule out the possibility that there is a small
fraction of receptors that did not incorporate free subunits.
We note that our data indicate that both the ␣/␤ and ␤/␣ concatemers
when expressed without free subunits behave as though receptors include three ␣4 subunits. This differs from the results obtained by Zhou et
al. (2003), who observed that the ␤/␣ receptor had a small EC50 for ACh.
We also confirmed by Western blot that concatemers do not significantly degrade into individual subunits in the oocytes (Fig. 3) (Zhou et
al., 2003; Carbone et al., 2009).
We sought to incorporate the free subunit selectively into a defined
position in the pentamer, either a position in which it contributed to an
agonist-binding site or one in which it did not. Accordingly, we confirmed the arrangements proposed by Zhou et al. (2003) for subunits in
receptors formed by a concatemer plus a free subunit (Fig. 1). To do this,
we used a mutation in the E-loop of the agonist-binding site contributed
by the ␤2 subunit, which we had previously shown to affect activation by
5I A85380 (␤2F119Q) (Hamouda et al., 2009). We expressed ␤2F119Q
with each concatemer and determined activation by 5I A85380 and ACh.
As shown in Figure 4, when ␤2F119Q is expressed with the ␤/␣ concatemer, activation is indistinguishable from when wild-type ␤2 is expressed.
In contrast, when expressed with the ␣/␤ concatemer, activation by 5I
A85380 is shifted toward higher concentrations and lower efficacy. The
EC50 for activation by ACh is not affected [5 ⫾ 1 M (five cells) for
␣/␤&␤2F119Q and 9 ⫾ 3 M (seven cells) for ␤/␣&␤2F119Q], as expected from results with free subunits (Hamouda et al., 2009). These
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A

Figure 2. The free subunit participates in the assembled receptor, as indicated by responses
to agonists. The relative response to 5I A85380 is plotted against the EC50 for ACh; when the
receptor contains three ␤2 subunit N-terminal domains, the relative response is large, and the
EC50 is small (free subunits with an ␣4:␤2 ratio of 1:8; black square). Conversely, when two ␤2
subunits are present, the relative response is small and the EC50 is large (free subunits with an
␣4:␤2 ratio of 8:1; black triangle). The hollow squares show data for combinations in which it
is predicted that three ␤2 subunit N-terminal domains would be present if receptors contained
two copies of a concatemer and a single copy of the free subunit, whereas hollow triangles show
data for receptors with two predicted ␤2 N-terminal domains. The black circles show data for
the two concatemers expressed without a free subunit. The means of values with two predicted
␤2 N termini are 5I A85380 relative response of 0.30 ⫾ 0.04 (N ⫽ 14 combinations) and
EC50 ⫽ 97 ⫾ 9 M, whereas with three predicted ␤2 N termini the means are 1.47 ⫾ 0.08
(N ⫽ 9 combinations) and 6.2 ⫾ 2.7 M. The means differ at p ⬍ 10 ⫺6 for each parameter.
Data show mean ⫾ SE, for 27 combinations of constructs (data from 3 or more oocytes),
including concatemers alone and combinations of free subunits. The full data set is shown in
supplemental Table 1 (available at www.jneurosci.org as supplemental material).

Figure 3. Concatemers do not appear to be significantly degraded. The panels show two
blots of the same transfer of proteins extracted from four batches of oocytes, injected with
different constructs on the same day. In A, the transfer was probed with antibody to ␣4 (H-133;
sc5591). In B, the transfer was stripped and reprobed with antibody to ␤2 (C-20; sc1449). Note
that there appears to be some breakdown of ␣4 in extracts from oocytes injected with ␣4&␤2
subunits. However, it does not appear that concatemers break down to a significant extent. For
each preparation, 50 oocytes were used. Approximately 230 g (⬃20% of preparation) of
protein loaded in lanes 2, 3, and 4, and ⬃50 g in lane 1 (⬃5% of prep). These images are
representative of eight gels from three protein preparations. Images are shown in grayscale and
reversed intensity scale to allow visualization of minor bands.
observations confirm the proposed arrangement (Zhou et al., 2003), that
the free subunit contributes to an agonist-binding interface when expressed with the ␣/␤ concatemer but not the ␤/␣ concatemer (Fig. 1).

Results
Previous studies of the ability of 17␤-estradiol to potentiate the
nicotinic ␣4␤2 receptor have found that potentiation requires a
specific sequence at the C-terminal of the ␣4 subunit (Paradiso et
al., 2001; Curtis et al., 2002). Mutagenesis of the sequence (Paradiso et al., 2001) demonstrated that not only a specific set of
residues is required but that the position of the sequence with

B

Figure 4. Activation by 5I A85380 indicates positions of subunits in receptors containing
concatemers. A shows the relative gating (normalized to the response to 1 mM ACh for the tested
cell) for ␣/␤ concatemers assembled with wild-type ␤2 (black triangles and solid black line) or
with ␤2F119Q (hollow triangles and dashed line). The parameters for a Hill equation fit to the
data are as follows: EC50, 8 ⫾ 1 nM; maximal response, 1.44 ⫾ 0.07-fold for ␤2; and EC50,
127 ⫾ 14 nM; maximal response, 1.13 ⫾ 0.11-fold for ␤2F119Q (the Hill coefficient was
constrained to 1 for fits). The hollow circles show responses of the ␣4/␤2 concatemer expressed alone. B shows comparable data for the ␤/␣ concatemer expressed with ␤2 or ␤2
F119Q. The parameters for a Hill equation fit to the data are as follows: EC50, 29 ⫾ 12 nM;
maximal response, 1.44 ⫾ 0.10-fold for ␤2; and EC50, 16 ⫾ 1 nM; maximal response, 1.29 ⫾
0.04-fold for ␤2F119Q (the Hill coefficient was constrained to 1 for fits). Fit parameters and data
points are mean ⫾ 1 SE, for data from six cells.

respect to the final (fourth) transmembrane helix is critical: insertion or deletion of a single residue to move the domain further
from or closer to the external end of the helix abolishes potentiation. Finally, addition of even a single residue at the end of the
domain also abolishes potentiation by 17␤-estradiol.
In light of these observations, our initial hypothesis was that
potentiation requires that the C-terminal domain must be placed
on an ␣4 subunit and, additionally, that the ␣4 subunit must
participate in ACh binding. To test this hypothesis, we need to
control the number and position of mutated subunits in the assembled receptor. The use of concatemeric constructs of subunits
(Zhou et al., 2003; Carbone et al., 2009) allows this control. We
generated two concatemers, one with the ␣4 subunit at the N
terminus (referred to as ␣/␤) and the other with the ␤2 subunit at
the N terminus (␤/␣) using the approach developed by Zhou et
al. (2003) (see Materials and Methods). Our characterization of
the concatemers demonstrates that the functional receptors generated when a concatemer is expressed with a free subunit show
the properties of a receptor that includes two copies of the concatemer with one copy of the free subunit (see Materials and
Methods). Furthermore, the use of a point mutant in the ␤2
subunit confirmed the subunit positions defined by Zhou et al.
(2003) (see Materials and Methods) (Fig. 1). When a free subunit
is expressed with the ␤/␣ concatemer, it will occupy the structural
(non-agonist-binding) position in the receptor, whereas with the
␣/␤ subunit it will occupy an agonist-binding position (Fig. 1).
The concentration of ACh used to elicit responses and to test
potentiation was relatively low (0.1 to 1 M) and, for almost all
constructs, elicited ⬍20% of the response to 1 mM ACh (supplemental Table 2, available at www.jneurosci.org as supplemental
material). We used 10 M 17␤-estradiol as the standard test concentration of potentiator.
Sample traces of potentiation for the most important combinations of constructs are shown in Figure 5. The data for the
potentiation ratios for all combinations studied are shown in
supplemental Table 2 (available at www.jneurosci.org as supplemental material).
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Figure 5. The responses to ACh and ACh plus 10 M 17␤-estradiol are shown for oocytes injected with selected combinations
of subunits. The times of drug application are indicated by the horizontal bars above the traces: the top bar shows the application
of a low concentration of ACh alone, whereas the bottom bar shows the application of ACh plus 10 M 17␤-estradiol. The left
column shows responses from oocytes injected with the ␣/␤ concatemer and different free subunits; in this combination the free
subunit contributes to an ACh-binding site. Note that a single copy of wild-type ␣4 produces a receptor that is potentiated by
17␤-estradiol, whereas ␤2 does not, and swapping the portions of the subunit from the end of M3 to the C terminus transfers
potentiation or lack thereof. Calibration (top panel): 10 s (all panels); 260 nA (␣/␤&␣4), 34 nA (␣/␤&␤2), 29 nA (␣/␤&␣-M3␤), 14 nA (␣/␤&␤-M3-␣). The right column shows responses from oocytes injected with the ␤/␣WLAAC concatemer and
different free subunits; in this combination, the free subunit occupies the structural position. Note that a single copy of wild-type
␣4 produces a receptor that is potentiated by 17␤-estradiol, whereas ␤2 does not, and swapping the last six residues from ␣4 to
␤2 transfers potentiation. Calibration (top panel): 10 s (all panels); 1800 nA (␤/␣WLAAC&␣4), 68 nA (␤/␣WLAAC&␤2), 11 nA
(␤/␣WLAAC&␤WLAGMI).

17␤-Estradiol potentiation is conferred whether the ␣4
subunit participates in ACh binding or serves as the
structural subunit
We confirmed that the ␣/␤ concatemer, expressed alone, is not
potentiated by 10 M 17␤-estradiol, whereas the ␤/␣ concatemer
is (Zhou et al., 2003) (Table 1). This indicates that potentiation
requires one or more intact, untethered C-terminal domains on
the ␣4 subunit. When the ␣/␤ concatemer is expressed with free
␤2 subunit (abbreviated as ␣/␤&␤2), potentiation is also absent,
whereas coexpression of the ␣/␤ concatemer with free ␣4 subunit
results in potentiation (Fig. 5, Table 1). This observation indicates that a single intact ␣4 C terminus is sufficient to allow some
potentiation. Overall, comparing ␤/␣&␣4 to ␣4&␤2 (8:1) indicates that potentiation for the ␤/␣&␣4 receptor is greater than for
receptor composed of free subunits ( p ⫽ 0.04) as well as for
␤/␣&␤2 compared with ␣4&␤2 (1:8) receptors ( p ⫽ 0.01).
Coexpression of the ␣/␤ concatemer with free ␣4 subunit
results in a receptor in which the ␣4 subunit that has an intact C
terminus also participates in forming an ACh-binding interface
(Fig. 1). To determine whether this is required, we tested additional constructs.
The first manipulation tested the effects of a mutation of the
␣4 subunit C terminus. Potentiation by 17␤-estradiol is lost
when the ␣4 C-terminal WLAGMI is mutated to WLAAC (abbreviated ␣WLAAC) (Paradiso et al., 2001). Expression of
␣WLAAC with ␣/␤ removes potentiation (Fig. 6), as expected.
We then mutated the untethered C terminus of the ␣4 subunit in
the ␤/␣ concatemer (␤/␣WLAAC). When the ␤/␣WLAAC concatemer is expressed with free ␣4, potentiation is present, but not
when it is expressed with free ␤2 (Fig. 6). These observations

indicate that potentiation can occur
whether the ␣4 subunit contributes to an
agonist-binding interface (when expressed
with the ␣/␤ concatemer) or acts as a structural subunit (when expressed with the
␤/␣WLAAC concatemer). They also confirm that only a single subunit need contain the WLAGMI sequence to underlie
potentiation.
Incorporation of a single ␣4 subunit
with an untethered WLAGMI domain confers estradiol potentiation on the receptor. We compared two combinations of
constructs. In the case of ␣/␤&␣4 to
␣/␤&␣4WLAAC, the difference in potentiation ratio is significant at p ⫽ 5 ⫻
10 ⫺8 (t test). For ␤/␣WLAAC&␣4 to
␤/␣WLAAC&␣4WLAAC, the difference is
significant at p ⫽ 8 ⫻ 10 ⫺7. These observations support the conclusion that free ␣4
subunits incorporate efficiently when expressed with either concatemer.

A 17␤-estradiol binding element can be
placed on either ␣4 or ␤2 subunits
We then examined the question of whether
potentiation required the rest of the ␣4 subunit or was based on the C-terminal region
alone. The initial constructs were chimeric subunits between ␣4 and ␤2 subunits,
with a join just after the end of the third
membrane spanning region (abbreviated ␣-M3-␤ and ␤-M3-␣) (Fig. 1). In
these chimeras, the N-terminal extracellular domain and the
first three transmembrane domains are from one subunit,
whereas the large cytoplasmic loop, the fourth transmembrane domain and the C-terminal tail are transferred. As expected, replacing the C-terminal domain of the ␣4 subunit
with sequence from ␤2 removes potentiation when expressed
with the ␣/␤ concatemer (Figs. 5, 6; supplemental Table 2,
available at www.jneurosci.org as supplemental material).
More surprisingly, transferring the ␣4 sequence to ␤2 confers
potentiation (Fig. 6). This observation indicates that the
N-terminal extracellular domain and the first three transmembrane domains are not sufficient for potentiation. Potentiation is transferred whether the free subunit occupies the
structural position or contributes to an agonist-binding interface (Fig. 6).
We constructed two additional chimeric subunits. These involved transferring the fourth transmembrane segment plus the
WLAGMI sequence (␤M43 C) from the ␣4 subunit to the ␤2
subunit, or only the WLAGMI sequence (␤WLAGMI). The 6 aa
sequence was transferred, as previous work has indicated that the
length of the C-terminal sequence is critical for potentiation
(Paradiso et al., 2001). Both of these chimeras allow potentiation
when expressed with the ␤/␣WLAAC or the ␣/␤ concatemer
(Fig. 6). These data indicate that the terminal residues are critical
for potentiation. However, the amount of potentiation is significantly greater for the ␤M43 C construct than for ␣4 or
␤WLAGMI when expressed with either the ␣/␤ or ␤/␣WLAAC
concatemers, and for ␤-M3-␣ expressed with ␣/␤ (one-way
ANOVA for each concatemer separately, with Bonferroni’s cor-
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These conclusions are tentative, given the relatively small number
of cases examined and the possibility for confounding factors.
Our observations indicate that potentiation can occur when
only a single copy of a free WLAGMI domain is incorporated in
the assembled receptor. Furthermore, the WLAGMI sequence
can be placed on the ␣4 or ␤2 subunit, and the subunit can
participate in forming an agonist-binding interface or serve as the
fifth, structural, subunit. There are trends suggesting that potentiation may be larger when the receptor includes concatemers,
and may be larger when the domain is present on a ␤2 subunit
rather than an ␣4 subunit. There is also an indication that some
portions of the ␣4 cytoplasmic loop (between the third and
fourth transmembrane regions) might reduce potentiation,
whereas some portions of the fourth transmembrane region may
enhance potentiation. These observations suggest the existence of
additional factors that influence the extent of potentiation, which
will have to be examined in additional experiments.

Figure 6. Transferring the ␤2 C terminus to ␣4 removes potentiation by 17␤-estradiol, and
transferring the ␣4 C-terminal domain to ␤2 confers potentiation. Combinations of constructs
were chosen in which there are no free WLAGMI domains except in the added free subunit.
When expressed with the ␣/␤ concatemer, the free subunit occupies a position in which it
contributes to an ACh-binding site, whereas when expressed with the ␤/␣WLAAC concatemer
it occupies the structural position (Fig. 1). The figure shows the mean response ratio in the
presence of 10 M 17␤-estradiol (⫹1 SE). The labels for the bar show the combination of
constructs expressed and the number in parentheses shows the number of free C-terminal
domains in the postulated pentamer. The significance levels are shown on the right for the
probability that the ratio differs from 1 (no effect, shown by the heavy dashed line): ns, p ⬎
0.05; *p ⬍ 0.05; **p ⬍ 0.01; ***p ⬍ 0.001. The numbers of oocytes tested is shown in
parentheses after the significance level. The two dashed lines indicate a response ratio of 1 (no
effect; heavy line) or the mean level for free wild-type ␣4 expressed with that concatemer (thin
line). Full data are shown in supplemental Table 2 (available at www.jneurosci.org as supplemental material).

rection). We note, however, that mutation of WLAGMI to
WLAAC in the intact ␣4 subunit removes potentiation.
We noted that transferring the WLAGMI sequence to ␤2 resulted in the C-terminal sequence QPWLAGMI. Previous work
(Paradiso et al., 2001) showed that mutation of both prolines in
␣4 (PPWLAGMI to AAWLAGMI) abolishes potentiation, so we
mutated the glutamine to proline in ␤2WLAGMI to produce
␤2PPWLAGMI. Expression of the resulting construct did not
increase potentiation to the same level as seen with the ␤M43 C
mutation (Fig. 6).
Overall, these data indicate two points. First, transfer of the
TM4 region plus the tail produces more potentiation than the
simple transfer of the C-terminal tail. Second, the cytoplasmic
loop of the ␣4 subunit (from the end of TM3 to the start of TM4)
appears to diminish potentiation compared with the amount
produced when only the TM4 to the C terminus is transferred.
The observation that the WLAGMI domain can be moved
from one subunit to another is quite surprising. Our data suggest
that potentiation does not differ greatly depending on whether
the tail is placed on the ␣4 or ␤2 subunit. Pooling the data for
receptors containing single copies of WLAGMI, the mean values
for potentiation are, for ␤2 N-terminal constructs, 2.3 ⫾ 0.3-fold
(mean ⫾ SE; N ⫽ 8 combinations of constructs), and, for ␣4
N-terminal constructs, 1.6 ⫾ 0.1-fold (N ⫽ 2) ( p ⫽ 0.03). Similarly, it does not appear to matter whether the domain is placed
on the structural subunit (mean potentiation, 2.4 ⫾ 0.5-fold;
four combinations) or on a subunit contributing to an AChbinding interface (2.0 ⫾ 0.2-fold; six combinations) ( p ⫽ 0.8).

Relationship between copy number and potentiation
There is a significant increase in potentiation as the total number
of WLAGMI C-terminal domains increases in a pentameric
receptor. The average value for potentiation by 10 M 17␤estradiol increases from 0.97 ⫾ 0.02 (0 domains, 10 combinations tested) to 2.2 ⫾ 0.2 (1 domain, 10), 2.4 ⫾ 0.4 (2 domains, 5),
3.3 ⫾ 0.2 (3 domains, 4), to 3.7 ⫾ 0.3 (5 domains, 3). Regression
of potentiation on the number of untethered domains gives a
slope of 0.6 (p ⬍ 10 ⫺7 that the slope is zero).
Our data were obtained using a constant concentration of
17␤-estradiol, and it is possible that changes in both potency and
efficacy occurred for some of the constructs. Accordingly, we determined the concentration– effect relationship for 17␤-estradiol
for combinations of subunits that have one to five untethered
WLAGMI sequences. Two combinations of constructs were
tested for each number of untethered WLAGMI. The combinations were chosen to keep the number of ␤2 N termini constant at
2 in the assembled pentamers, but some combinations were
formed without the use of concatemers and the domains were
placed on agonist-binding or structural subunits. The concentration–potentiation data are shown in Figure 7, and the fit parameters are given in Table 2.
The fit maximal potentiation is plotted against the number of
untethered WLAGMI domains in Figure 8. There is a clear
increase in maximal potentiation with increasing untethered
WLAGMI. The increase is greater than linear, with each added
untethered WLAGMI increasing the potentiation by ⬃1.6-fold.
The geometric fit shown in Figure 8 is a better description than
the linear fit, although there is an indication that the increase
from three to five domains is not as great as might be expected.
This could result from several possible factors. Some are technical, for example as a result of particular constructs providing a
somewhat greater or lesser amount of potentiation than others.
However, it is also possible that there is a “ceiling” on the amount
of potentiation. This could arise because there is a maximal potentiation possible by the mechanism used by estradiol (so that
five domains occupied by 17␤-estradiol would not be 1.6 2 as
efficacious as three), or it could be that there is some interaction
among bound estradiols so that there is a maximal possible number that can bind. Additional experiments will be necessary to
distinguish among these possibilities.
Our test concentration of 17␤-estradiol (10 M) is not a saturating concentration for any of these constructs. Accordingly,
the potentiation ratios we calculate for the screening data may
reflect both efficacy and potency. However, the qualitative con-
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Figure 7. An increased number of free WLAGMI domains results in increased maximal potentiation by 17␤-estradiol. Potentiation is plotted against the concentration of 17␤-estradiol
for eight combinations of constructs. A shows data for receptors containing one (␤/
␣LAAC&␤WLAGMI and ␣/␤&␣4; solid lines show fits) or three (␣4&␤2 8:1 and
␤/␣&␤M43 C; dash-dot lines) free WLAGMI domains. B shows data for two
(␣WLAAC&␤WLAGMI 8:1 and ␤/␣&␤-M3-␣; dash-dot-dot lines) or five (␣4&␤2WLAGMI
8:1 and ␣4&␤M43 C 8:1; dashed lines) domains. The number of free WLAGMI domains in
each combination is shown in parentheses. The lines show fits of the equation r ⫽ 1 ⫹
Rmax([␤Est]/(EC50 ⫹ [␤Est]), where R is the response ratio, Rmax is the maximal ratio, [␤Est] is
the concentration of 17␤-estradiol, and EC50 is the concentration producing a half-maximal
effect. (The Hill coefficient was constrained to 1.) The fit values are shown in Table 2. The points
show the mean ⫾ SE, and the dashed line at a ratio of 1 shows no effect.

clusions about placement of the untethered WLAGMI domain
are clear.
Potentiation by 17␣-vinylestradiol
The steroid analog 17␣-vinylestradiol also potentiates the ␣4␤2
receptor. Previous work (Paradiso et al., 2001) has found that
potentiation by this analog does not require the final four residues of the ␣4 C terminus, although potentiation is larger when
the AGMI sequence is present. To remove potentiation, it is necessary to also mutate a tryptophan residue just preceding the terminal
sequence (i.e., to convert WLAGMI to LLAAC). Mutation only of
the tryptophan (to LLAGMI) does not reduce potentiation by either
17␣-vinylestradiol or 17␤-estradiol, emphasizing the overall greater
importance of the AGMI sequence for potentiation (Paradiso et al.,
2001). Assuming that the transduction mechanism is the same for
potentiation by 17␣-vinylestradiol or 17␤-estradiol, these observations indicate that neither the AGMI sequence nor the critical tryptophan is required for the transduction of molecular recognition
into functional potentiation. Accordingly, this steroid analog pro-
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Table 2. Concentration dependence for potentiation by 17␤-estradiol
Combination
Rmax ⫹ 1
EC50
Constructs

No. free WLAGMI

Mean

SE

Mean

SE

N

␣/␤&␣4
␤/␣WLAAC&␣4
␤/␣&␣-M3-␤
␣WLAAC&␤WLAGMI 8:1
␣4&␤2 8:1
␤/␣&␣4
␣4&␤WLAGMI 8:1
␣4&␤M43 C 8:1

1
1
2
2
3
3
5
5

1.54
2.04
2.96
2.97
5.00
5.81
7.19
13.44

0.1
0.1
0.2
0.2
1.0
0.3
0.6
1.0

23.3
9.4
4.5
21.1
8.0
6.3
19.0
39.2

5.7
3.1
0.6
3.5
1.1
1.0
3.4
13.6

6
4
9
7
4
7
4
4

The first column names the constructs injected. The next column lists the number of free C-terminal WLAGMI
sequences predicted to be in the assembled receptor. The next columns give the parameters obtained from fitting
the concentration– effect relationships (Fig. 7) with the equation R ⫽ 1 ⫹ Rmax(关␤Est兴/(EC50 ⫹ 关␤Est兴), where R
is the response ratio, Rmax is the maximal ratio, 关␤Est兴 is the concentration of 17␤-estradiol, and EC50 is the
concentration producing a half-maximal effect. The mean values shown are the means of fits to data from N oocytes
injected with that combination. An ANOVA with Bonferroni’s correction indicates that the value for EC50 is larger for
␣4&␤M43 C than for all other combinations except for ␣/␤&␣, ␣WLAAC&␤WLAGMI, and ␣4&␤WLAGMI. EC50
for ␣/␤&␣4 is larger than for ␤/␣&␣-M3-␤, but no other differences are significant. For values of Rmax , the value
for ␣4&␤M43 C is larger than that for all other combinations. Otherwise, values for combinations with one or two
free WLAGMI do not differ significantly from each other, nor do values for three or five free WLAGMI. All values for
combinations with one or two free WLAGMI were significantly less than all combinations with three or five, except
for ␣WLAAC&␤WLAGMI 8:1 whose value for Rmax does not differ significantly from that for ␣4&␤2 8:1.

Figure 8. An increased number of free WLAGMI domains results in increased maximal potentiation by 17␤-estradiol. The fit Rmax ⫹ 1 is plotted against the number of free WLAGMI
domains predicted to be in the assembled receptor. The data were fit with two simple equations. The first is a linear increase (Rmax ⫹ 1) ⫽ 1 ⫹ sM, where Rmax is the fit maximal
potentiation, s is the constant of proportionality, and M is the number of free WLAGMI domains.
The second is a geometric increase (Rmax ⫹ 1) ⫽ rM, where r is the relative increase in Rmax
conferred by adding one WLAGMI domain. The lines show the predicted dependence (dashed
linear, solid geometric) and the dashed lines show ⫾1 SE of the fits. The fit values are s ⫽ 1.6 ⫾
0.1 (best fit ⫾ 1 SE of parameter estimate) and r ⫽ 1.62 ⫾ 0.02. The geometric fit was better
than the linear fit ( p ⫽ 0.02, F test). Points show mean ⫾ SE for data shown in Table 2. Note
that the symbol is sometimes larger than the error bar, and that the two data points at two free
WLAGMI overlap. The symbols match those in Figure 7.

vides a control to indicate that the transduction mechanism
for potentiation is preserved when potentiation by 17␤estradiol is removed.
We tested a number of the combinations described above (a
total of 17) (supplemental Table 3, available at www.jneurosci.
org as supplemental material) and found that 17␣-vinylestradiol
potentiates all of them. For the five cases in which there are no
untethered AGMI and two or three critical tryptophans, the
mean potentiation by 17␣-vinylestradiol is 2.3 ⫾ 0.6, whereas
17␤-estradiol on average has no effect (0.94 ⫾ 0.04). Overall,
potentiation increases with increasing numbers of critical tryptophans (associated with increasing numbers of untethered
AGMIs) from 3.1 ⫾ 1.5 (N ⫽ 2) for two tryptophans, to 6.1 ⫾ 1.7
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(N ⫽ 11) for three tryptophans, and 7.7 ⫾ 2.7 (N ⫽ 4) for five
tryptophans, although the regression coefficient (1.2 ⫾ 1.3; fit
value ⫾ estimated SE of parameter) is not significantly different
from 0 ( p ⫽ 0.39).
We tested a subset of additional constructs in which the critical
tryptophan was mutated. These were ␣LLAAC and ␤/␣LLAAC.
These constructs allowed us to test the effect of increasing numbers
of critical tryptophans in the absence of an untethered AGMI sequence, again holding the number of subunits with ␤2 N termini
constant at 2. The mean potentiation increased steadily with increasing numbers of tryptophans: ␤/␣LLAAC&␣LLAAC (zero tryptophans: 1.16 ⫾ 0.03, five oocytes); ␤/␣LLAAC&␣WLAAC (one:
1.20 ⫾ 0.09, four); ␤/␣WLAAC&␣LLAAC (two: 1.56 ⫾ 0.15, four);
␤/␣WLAAC&␣WLAAC (three: 1.76 ⫾ 0.05, four). Linear regression of potentiation on the number of critical tryptophans for this
subset gives a regression coefficient of 0.22 ⫾ 0.04, which differs
from zero ( p ⫽ 0.04).
Overall, the most significant observation is that removal of
potentiation by 17␤-estradiol does not remove potentiation by
17␣-vinylestradiol, indicating that the transduction mechanism
is retained.

Discussion
The goal of this study was to identify the critical portions of the
nicotinic ␣4 and ␤2 subunits required for potentiation by 17␤estradiol. We extended previous studies that had determined that
the C-terminal tail of the ␣4 subunit is necessary (Paradiso et al.,
2001; Curtis et al., 2002). Our starting hypothesis was that potentiation would be subunit specific and likely would require that the
specific sequence be present on a subunit in a particular position
(e.g., on an ␣4 subunit involved in forming an agonist-binding
site). To our surprise, this hypothesis is incorrect in both respects.
The results indicate that the WLAGMI domain can be placed at
the C terminus of either the ␣4 or ␤2 subunit to subserve potentiation. In addition, the subunit can participate in forming an
agonist-binding site or serve as the fifth, structural, subunit in the
receptor. As a corollary to these observations, the subunit with
the domain can be placed between ␤2 and ␣4 subunits or ␣4 and
␤2 subunits in the assembled receptor, so potentiation does not
appear to require a particular neighbor subunit.
Several observations support the idea that 17␤-estradiol interacts with the receptor at the AGMI sequence. Because 17␤estradiol is a hydrophobic molecule, it can interact with the lipid
membrane. However, the enantiomer of 17␤-estradiol does not
potentiate (Paradiso et al., 2001). This enantioselectivity indicates that potentiation requires interaction of steroid with an
optically active site, perhaps on the receptor. Potentiation is also
extremely sensitive to the structure of the WLAGMI domain—
mutations, insertions, or deletions can greatly reduce potentiation. In addition, potentiation by 17␣-vinylestradiol is reduced
but not removed by mutation of AGMI (Paradiso et al., 2001; this
study). To remove potentiation by 17␣-vinylestradiol, it is necessary to mutate both the AGMI sequence and the neighboring
tryptophan. This observation indicates that the AGMI sequence
is not required for transduction, in that 17␣-vinylestradiol still is
capable of potentiation. Furthermore, the finding that complementary changes in steroid and receptor structures affect potentiation supports the idea that the D ring of the steroid associates
with the C-terminal WLAGMI tail to underlie potentiation. Finally, the present observations indicate that moving this defined
domain from one subunit to another can transfer potentiation.
Overall, these data support the conclusion that the C-terminal
domain is involved in molecular recognition (binding) rather
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than the conversion of binding at a different site into functional
potentiation (transduction). However, previous work from our
laboratory (Paradiso et al., 2001) has shown that the molecular
structure of the A ring (the “other end” of the steroid molecule)
also is important for potentiation. The binding domain for the A
ring has not been localized, although the present data suggest that
it must be either to a sequence that is found in both the ␣4 and ␤2
subunits, or possibly lies in the membrane. Accordingly, it seems
most appropriate to call the C-terminal sequence a binding element or binding domain.
It is surprising that potentiation can be transferred between
subunits simply by moving the WLAGMI sequence. Previous
studies of potentiating drugs show more specificity in sites. Several potentiators interact with receptors in this gene family at
subunit interfaces in the extracellular region. The classic example
is benzodiazepine potentiation of GABAA receptor function (Sigel and Buhr, 1997), but potentiation of nicotinic ␣3␤4* receptors by morantel (Seo et al., 2009) or ␣43␤22 receptors by Zn 2⫹
ions (Moroni et al., 2008) also requires specific residues in the
two subunits forming an interface. For more hydrophobic compounds, etomidate appears to interact with transmembrane regions of two subunits in the GABAA receptor to potentiate (Li et
al., 2006), whereas potentiating neurosteroids are proposed to
interact with two transmembrane domains of a single GABAA
subunit (Hosie et al., 2006). This estradiol-binding element appears to be remarkably discrete and effective at transferring
potentiation.
There are additional parts of the subunit(s) that appear to
influence the amount of potentiation (Curtis et al., 2002). The
cytoplasmic loop of the ␣4 subunit may reduce the amount of
potentiation transferred. This effect might result from an action
of the loop on transduction of potentiation, as there have been
reports in receptors in this family that the cytoplasmic loop can
affect channel function (Bouzat et al., 1994; Wang et al., 2000;
Kuo et al., 2005; Hales et al., 2006) or modulation (Swope et al.,
1999; Yevenes et al., 2008). In contrast, the TM4 helix of the ␣4
subunit appears to increase potentiation. As will be discussed
below, the action of 17␤-estradiol to potentiate responses may
result from an effect on the transmembrane helices to stabilize the
open-channel state of the receptor. Accordingly, the structure of
the TM4 region may influence the transduction mechanism. Alternatively, it might be that the A ring of the steroid interacts with
some of the residues in the TM4 region. Additional experiments
will be required to elucidate the bases for these effects.
The mechanism by which potentiation is produced is not
known. Single-channel studies have shown that there is no increase in the single-channel conductance (Curtis et al., 2002).
However, the probability of being open is increased, perhaps because of an increase in the duration of openings [Curtis et al.
(2002), their Fig. 4]. The increased probability of being open is
reminiscent of the effects of mutations of the conserved leucine at
the ninth residue in the second membrane-spanning region. Numerous studies have reported that mutation of TM2 L9⬘ to more
hydrophilic residues increases the open probability of nicotinic
and related receptors (Revah et al., 1991; Labarca et al., 1995;
Chang et al., 1996). The increase is produced by a mutation in any
of the five subunits in the receptor, and the overall effect increases
with number of mutated subunits (Labarca et al., 1995; Chang et
al., 1996; Moroni et al., 2006). These observations indicate that all
five subunits contribute to a conformational change before the
channel becomes permeable for ions and that the L9⬘ mutation in
any subunit therefore can shift the overall gating equilibrium.
Perhaps the interaction with estradiol produces a conformational
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change in the transmembrane regions of that subunit that results
in a similar stabilization of the open state. The observation that
the extent of potentiation (efficacy) increases with increased
numbers of untethered WLAGMI regions is consistent with this
suggestion. The data suggest that each untethered WLAGMI increases the maximal potentiation by ⬃1.6-fold. The idea of an
independent action of 17␤-estradiol on any subunit that carries
an available WLAGMI sequence accounts well for the essential
features of our observations.
Drugs that enhance the response of synaptic receptors, without directly interacting with the agonist-binding site, are of increasing interest as therapeutic agents that do not produce a
response directly but enhance endogenous signaling. A number
of drugs that enhance GABAA receptor activity are in clinical use
as tranquilizers, sedatives, or hypnotics, first represented by the
benzodiazepines (Rudolph and Möhler, 2004). More recently,
potentiators of the nicotinic ␣7 receptor have received attention
as possible agents to enhance cognition and memory (Lightfoot
et al., 2008). The nicotinic ␣4 subunit is quite prevalent in the
mammalian brain; the receptor comprising ␣4 and ␤2 subunits is
the most common heteromeric receptor and the ␣4 subunit also
participates in forming a variety of receptors of more complex
stoichiometry (Gotti et al., 2007). These receptors have their major physiological effects by modulating the release of other neurotransmitters, rather than directly mediating postsynaptic
responses in the brain (Dani and Bertrand, 2007). In particular, a
role for ␣4-containing receptors in control of dopamine release
has been proposed (Exley and Cragg, 2008), providing a possible
link to the reward pathway. The actions of endogenous compounds, particularly steroids, are more difficult to define compared with the effects of exogenously added drugs. There are two
principal difficulties in demonstrating a physiological role for
estradiol potentiation specifically of ␣4-containing nicotinic receptors. The first is that the concentration of 17␤-estradiol required for potentiation is high (⬎1 M), much higher than the
levels in the brain (⬃1 nM) (Mukai et al., 2006), although local
synthesis clearly occurs (Mukai et al., 2006; Cornil and Charlier,
2010) and could result in higher local levels. The second is that
17␤-estradiol has a multiplicity of effects in the nervous system,
both in sculpting development (cf. Gillies and McArthur, 2010)
and in more rapid changes in function (cf. Mukai et al., 2006;
Cornil and Charlier, 2010; Gillies and McArthur, 2010).
Overall, these observations indicate that the interaction between 17␤-estradiol and the nicotinic ␣4␤2 receptor is mostly
determined by the discrete, C-terminal tail of a subunit. The
ability to transfer potentiation between subunits and the relationship between numbers of WLAGMI domains and efficacy of potentiation suggest that the effect of 17␤-estradiol is mediated by
actions on single subunits and that the overall consequences for
gating occur because of the summation of independent energetic
contributions to overall gating of this receptor.
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